Sino Biological/SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody, Mouse Mab/1/40591-MM43
商品编号:
40591-MM43
品牌:
sinobiological
市场价:
¥0.00
美元价:
0.00
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody, Mouse Mab General Information
Product name
SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody, Mouse Mab
Validated applications
ELISA,Neutralization
Application notes
(Antibody"s applications have not been validated with corresponding viruses. Optimal concentrations/dilutions should be determined by the end user.)
Specificity
2019-nCoV Coronavirus spikeHas cross-reactivity in ELISA withSARS-CoV-2 (2019-nCoV) Spike RBD Protein (Catalog#40592-V08B)No cross-reactivity in ELISA withSARS-CoV Spike S1-mFc Protein (Catalog#40150-V08B1)SARS-CoV Spike RBD-His Protein (Catalog#40150-V08B2)MERS-CoV Spike S1 Protein (Cat# 40069-V08B1)HCoV-HKU1 (isolate N1) Spike S1 Protein (Cat# 40021-V08H)HCoV-HKU1 (isolate N5) Spike S1 Protein (Cat# 40602-V08H)HCoV-NL63 Spike S1 Protein (Cat# 40600-V08H)HCoV-229E Spike S1 Protein (Cat# 40601-V08H)HCoV-OC43 Spike S1+S2 ECD Protein (Cat# 40607-V08B)
Immunogen
Recombinant SARS-CoV-2 (2019-nCoV) Spike S1-mFc Protein (Catalog#40591-V05H1)
Preparation
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, Recombinant SARS-CoV-2 (2019-nCoV) Spike S1-mFc Protein (Catalog#40591-V05H1; YP_009724390.1; Val16-Arg685). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
Source
Monoclonal Mouse IgG1 Clone #43
Purification
Protein A
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Endotoxin
< 3="">
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.
SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody, Mouse Mab Validated Applications
Application | Dilution |
---|---|
ELISA | 0.5-1 μg/mL |
Notes
Microneutralizaiton (MN): | The neutralization activity is Measured by microneutralization assay in vitro. The virus microneutralizaiton (MN) test was performed on 293T-ACE2 cells infected with SARS-CoV-2 (2019-nCoV) Spike Pseudovirus under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# 40591-MM43). Rate of inhibition was determined by comparing the Relative Light Unit (RLU) of Luciferase reporter in different antibody concentrations. The IC50 is typically 1.41 µg/mL. |
Please Note: Optimal concentrations/dilutions should be determined by the end user.
SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody, Mouse Mab Images

Serial dilutions of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# 40591-MM43) was detected by SARS-CoV-2 (2019-nCoV) Inhibitor Screening ELISA Kit (Catalog# KIT001). The IC50 is typically 0.857 nM.

The neutralization activity is Measured by microneutralization assay in vitro. The virus microneutralizaiton (MN) test was performed on 293T-ACE2 cells infected with SARS-CoV-2 (2019-nCoV) Spike Pseudovirus under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# 40591-MM43). Rate of inhibition was determined by comparing the Relative Light Unit (RLU) of Luciferase reporter in different antibody concentrations. The IC50 is typically 1.41 µg/mL.
SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody, Mouse Mab: Synonyms
Anti-coronavirus spike Antibody; Anti-cov spike Antibody; Anti-ncov RBD Antibody; Anti-ncov s1 Antibody; Anti-ncov s2 Antibody; Anti-ncov spike Antibody; Anti-NCP-CoV RBD Antibody; Anti-NCP-CoV s1 Antibody; Anti-NCP-CoV s2 Antibody; Anti-NCP-CoV Spike Antibody; Anti-novel coronavirus RBD Antibody; Anti-novel coronavirus s1 Antibody; Anti-novel coronavirus s2 Antibody; Anti-novel coronavirus spike Antibody; Anti-RBD Antibody; Anti-S1 Antibody; Anti-S2 Antibody; Anti-Spike RBD Antibody
Coronavirus spike Background Information
The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, O-acetylated sialic acid. The spike is essential for both host specificity and viral infectivity. The term "peplomer" is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It"s been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.
References
- Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35.
- Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36.
- Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.
- Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and EndocytosisAuthorGorshkov, K;Susumu, K;Chen, J;Xu, M;Pradhan, M;Zhu, W;Hu, X;Breger, JC;Wolak, M;Oh, E;Year2020JournalACS NanoPubMed ID: 32845122FoldedExpand
- Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluationAuthorTan, X;Krel, M;Dolgov, E;Park, S;Li, X;Wu, W;Sun, Y;Zhang, J;Khaing Oo, M;Perlin, D;Fan, X;Year2020JournalBiosensors and BioelectronicsFoldedExpand
- Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In VivoAuthorZeng, C;Hou, X;Yan, J;Zhang, C;Li, W;Zhao, W;Du, S;Dong, Y;Year2020JournalAdv. Mater. WeinheimPubMed ID: 32875709FoldedExpand
- Screening Antibodies Raised Against the Spike Glycoprotein of SARS-CoV-2 to Support the Development of Rapid Antigen AssaysAuthorCantera, J;Cate, D;Golden, A;Peck, R;Lillis, L;Domingo, G;Murphy, E;Barnhart, B;Anderson, C;Alonzo, L;Glukhova, V;Hermansky, G;Barrios-Lopez, B;Spencer, E;Kuhn, S;Islam, Z;Grant, B;Kraft, L;Herve, K;de Puyraimond, V;Hwang, Y;Dewan, P;Weigl, B;Nichols, K;Boyle, D;Year2020JournalChemRxivFoldedExpand
If you couldn"t find the specific citation, you can:
- Find All Citations
- Submit a CitationGet a Publication Reward
- Leave Us a Message
Recombinant Antibody Production Service
High-throughput Recombinant Antibody Production
Large-scale Antibody Production
Antibody Development Service
Rabbit MAb Production Service
Mouse MAb Production Service
Rabbit PAb Production Service
Phospho-Specific Antibody
Anti-Idiotype Antibody
Fast Antibody Development Service
Mouse MAb
Rabbit PAb
More Antibody Production Service
Hybridoma Antibody Production
Chimeric Antibody
Antibody Fragment
Bispecific Antibody
We also have Immunoassay Service. Click to see more.
品牌介绍
北京义翘神州科技股份有限公司(Sino Biological Inc.)是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司,主要业务包括重组蛋白、抗体、基因和培养基等产品,以及重组蛋白、抗体的开发和生物分析检测等服务。义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。公司目前生产和销售的现货产品种类超过 4.6 万种,其中重组蛋白约 6,000 种,包括超过 3,800 种人源细胞表达重组蛋白产品,能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求;公司还能提供约 12,000 种抗体,其中单克隆抗体数量约 4,600 种,能够覆盖生命科学研究的多个领域,为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供「一站式」生物试剂产品和技术服务。义翘神州的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司,已成为生物试剂行业国内领先的科技公司之一。
联络我们